One good match permits another—why HLA-matched blood transfusion makes sense

por Reynolds, Ben C, Johnson, Sally A, Carter, Vaughan, Wallis, Jonathan P, Moghal, Nadeem E
Publicado 2013

SF3B1 Mutations Are Associated with Resistance to Non-Genotoxic MDM2 Inhibition in Chronic Lymphocytic Leukemia

por Aptullahoglu, Erhan, Wallis, Jonathan P., Marr, Helen, Marshall, Scott, Bown, Nick, Willmore, Elaine, Lunec, John
Publicado 2023

Splicing Modulation Results in Aberrant Isoforms and Protein Products of p53 Pathway Genes and the Sensitization of B Cells to Non-Genotoxic MDM2 Inhibition

por Aptullahoglu, Erhan, Ciardullo, Carmela, Wallis, Jonathan P., Marr, Helen, Marshall, Scott, Bown, Nick, Willmore, Elaine, Lunec, John
Publicado 2023

Non-genotoxic MDM2 inhibition selectively induces a pro-apoptotic p53 gene signature in chronic lymphocytic leukemia cells

por Ciardullo, Carmela, Aptullahoglu, Erhan, Woodhouse, Laura, Lin, Wei-Yu, Wallis, Jonathan P, Marr, Helen, Marshall, Scott, Bown, Nick, Willmore, Elaine, Lunec, John
Publicado 2019

Epigenome-wide analysis reveals functional modulators of drug sensitivity and post-treatment survival in chronic lymphocytic leukaemia

por Barrow, Timothy M., Nakjang, Sirintra, Lafta, Fadhel, Bilotkach, Kateryna, Woodhouse, Laura, Junge, Gesa, Tudhope, Susan J., Wallis, Jonathan P., Marr, Helen, Marshall, Scott, Bown, Nick, Willmore, Elaine, Strathdee, Gordon
Publicado 2020

PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia

por Herriott, Ashleigh, Tudhope, Susan J., Junge, Gesa, Rodrigues, Natalie, Patterson, Miranda J., Woodhouse, Laura, Lunec, John, Hunter, Jill E., Mulligan, Evan A., Cole, Michael, Allinson, Lisa M., Wallis, Jonathan P., Marshall, Scott, Wang, Evelyn, Curtin, Nicola J., Willmore, Elaine
Publicado 2015